![]() Trazodone is indicated for the treatment of depression and has been shown efficacious in reducing most symptoms associated with depression 1-3. The great availability of formulations allows to personalise trazodone administration according to patient profile characteristics. Orthostatic hypotension and headache are relatively common side effects. Somnolence/sedation, dizziness, consti- pation, and blurred vision are common side effects with an incidence slightly greater than 5%. In patients with Alzheimer’s disease or frontotemporal dementia, trazodone can help to handle behavioural symptoms, also acting as a putative neuroprotective agent. In patients with neurological conditions, trazodone helps to treat anxiety-depres- sive symptoms. It can help to improve insomnia and anxiety without resorting to benzodiazepines. In elderly patients, trazodone has reported excellent results, keeping high-quality standards for safety and tolerability. The maximum daily dose should not exceed 300 mg/day, split over two administra- tions across the day. formula- tion, and 50-100 mg for the P.R. In elderly patients, trazodone may be administered at very low dosages (25-50 mg/day for I.R. For COAD formulation, the starting recom- mended dose is 150 mg once daily. The initial dose of trazodone should range from 75 to 100 mg/day. The aim of this review was to summarise the pharmacological proper- ties of trazodone in improving depressive symptoms in elderly patients and in patients with neurological comorbidities, for whom secondary depression is often present.įive different pharmaceutical formulations of trazodone are available: intravenous or intramuscular liquid solution, immediate-release tablets (I.R.), oral drops, prolonged-release tablets (P.R.), and extended-release Contramid® tablets (COAD). Trazodone is indicated for the treatment of Major Depressive Disorder (MDD), often associated with anxiety, insomnia, agitation, nervousness, or irritability. Original investigation - until March 2020 ![]() Translational Research in Gerontology and Geriatrics - Hypothesis Papers Translational Research in Gerontology and Geriatrics - Clinical Guidelines Translational Research in Gerontology and Geriatrics - Reviews ![]() Translational Research in Gerontology and Geriatrics - Short Communications ![]() Translational Research in Gerontology and Geriatrics - Original Investigations Geriatrics and Gerontology Elsewhere - Hypothesis papers Geriatrics and Gerontology Elsewhere - Commentaries Geriatrics and Gerontology Elsewhere - Editorials doi:10.Clinical Geriatrics - Original InvestigationsĬlinical Geriatrics - Short CommunicationsĬlinical Observations in Geriatrics - Clinical Experiences and Case Reports An update on the use of sedative-hypnotic medications in psychiatric disorders. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation. Unintentional trazodone overdoses in children ≤6 years of age: data from poison center over a period of 16 years. Antidepressants and cardiovascular adverse events: A narrative review. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Histamine in the regulation of wakefulness. Rediscovering trazodone for the treatment of major depressive disorder. Trazodone for insomnia: a systematic review.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |